Cancer is one of the leading causes of morbidity and mortality worldwide with a significant economic impact which has been increasing in recent decades. Numerous expert groups and/or international organizations have developed guidelines on how to build effective cancer control mechanisms, while in the European Union the majority of countries have developed national programmes. In Poland, cancer is the second leading cause of death. Compared with other European countries, Poland is characterized by a relatively low cancer incidence ratio, yet in terms of mortality and survival ratios, the situation is much worse than the average. On 1 January 2015, an oncological therapy fast track was implemented in Poland, popularly known as the "oncological package." Its formal objectives were to improve access to and systemize the process of cancer diagnostics and treatment. The reform introduced some of the solutions existing in other European countries, including waiting time limits, patient pathways, multidisciplinary medical consultations, and a care coordinator position. The preliminary evaluation analyses suggest that after the reform implementation the average waiting time for diagnostics and treatment for patients covered by the new system was significantly shortened in comparison to those excluded. Further research evaluating the reform impact on quality and/or comprehensiveness of care are needed. with other European countries, Poland is characterized by a relatively low cancer incidence ratio. In the period 2000 to 2013, the ratio increased by 37%, but it is still relatively low (411 cases per 100 000 in 2013 compared with 559 in the EU). 15 However, in terms of mortality and survival ratios, the situation in Poland is one of the worst in
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Cancer is one of the leading causes of morbidity and mortality worldwide with a significant economic impact which has been increasing in recent decades. Cancer is one of the leading causes of morbidity and mortality worldwide with a significant economic impact which has been increasing in recent decades. 1 In Europe, approximately 20% of deaths are caused by cancers, while in 17 of the 28 European Union (EU) countries, cancer has overtaken cardiovascular disease as the leading cause of premature death. 2 There are also significant inequalities in access to and outcomes of cancer care both between and within the countries. [3] [4] [5] Numerous expert groups and/or international organizations have developed guidelines on how to build effective cancer control mechanisms, [5] [6] [7] [8] [9] while the majority of EU countries have developed national programmes. 10 In Poland, cancer is the second leading cause of death, and its burden on society is growing. 11 In 2015, cancer was responsible for approximately 24% of deaths among women and 27% among men in in Poland. 12 According to the National Cancer Registry data, the number of new cases detected and deaths per year increased between 1999 and 2015 by 46% and 23%, respectively, 13 while analysis conducted by the Polish Society of Oncology suggests that in 10 years' time cancer may become the first leading cause of premature death in Poland. 14 Compared with other European countries, Poland is characterized by a relatively low cancer incidence ratio. In the period 2000 to 2013, the ratio increased by 37%, but it is still relatively low (411 cases per 100 000 in 2013 compared with 559 in the EU). 15 However, in terms of mortality and survival ratios, the situation in Poland is one of the worst in
Europe. In the case of malignant neoplasms, in 2015, the standardized death rate was higher than in Poland in only four EU countries, and its value for Poland was nearly 17% higher than the EU average (304.5 and 260.6 per 100 000 people, respectively). In addition, this gap has been growing within the few last years-cancer standardized death rate in Poland in 2010 was less than 11% higher than the EU average. 12 The average 5-year cancer survival ratio in
Europe in the period of 2000 to 2007 was 55%, while in Poland that value was only 43%. 16 Although the ratio value for the four most common cancers (breast, cervical, colon, and rectal) is growing, Poland still lags behind other developed countries (the 5-year survival rate for Poland is at the very bottom of the OECD-31 country lists, while for cervical cancer it even takes last place). In the period of 2010 to 2014, the cervical cancer survival rate for Polish women was only 55.1%, while the best value in the EU (in Denmark) was nearly 70%. In the same period, the gaps between Poland and the EU country with the highest rate of survival for breast, rectal, and colon cancer were, respectively, 12.3, 15.0, and 18.2 percentage points.
17
The need to improve cancer care organization in Poland has been universally acknowledged for many years. It constituted a central issue of public debates involving external experts, patients and provider representatives, as well as policy makers. One of the major challenges of oncological care in Poland was long waiting times related to both diagnostics and treatment procedures. 18 For example in November 2014, the average waiting time for a magnetic resonance imaging (MRI) was 6.5 months, while for colonoscopy it was 5.3 months. 19 There were also issues related to inefficiency of the existing system. Więckowska et al 20 conducted analyses of cancer service utilization rates for the period 2011 to 2012 and concluded that there were numerous examples of excessive hospitalization for diagnosis, chemotherapy, and radiotherapy, which should have been provided in out-patient settings. These services accounted for 23% of total cancer care spending in the country. 20 As a consequence, the aspects of cancer care waiting time and the organization of services constituted the central issues of the implemented reforms. On 1 January 2015, an oncological therapy fast track was implemented, popularly known as the "oncological package." Its formal objectives were to improve access to and systemize the process of cancer diagnostics and treatment. The reform set maximum waiting time limits for both diagnostics and treatment introduced patient pathways and multidisciplinary medical consultations as well as a care coordinator position. In the long run, the reform aimed to improve cancer detection at early stages and thus reduce mortality and medical care costs. 21 
| AIMS AND METHODS
The aim of this paper is to evaluate the implementation of the 2015 oncological care organization reform in Poland.
The framework for the reform evaluation was developed based on review of both international guidelines as well as
European countries' practical experiences with reforms aimed at improving organization of cancer care. Basic recommendations on improving the organization of the Polish system are provided. of cancer control mechanisms, puts great emphasis on an integrated approach to all the dimensions of cancer care, and constitutes a strategic tool for governments and policy makers. 5 Review of the recommendations provided by all of the above initiatives indicates that oncological care constitutes a broad and extremely complex topic. The comprehensive approach includes four main, interrelated stages:
(1) health promotion and primary prevention; (2) screening and early detection; (3) integrated cancer care; and (4) finally, rehabilitation and palliative care (Table 1) . Each stage includes various components while the complete scheme of the organization of care is influenced by numerous additional, often external determinants. In general, experts emphasize that in order to build comprehensive cancer control systems, good governance is a prerequisite. The diverse elements of cancer care must be coordinated and equipped with sufficient resources needed for both service delivery (financial and human resources) as well as planning and monitoring objectives (data and information systems), while the system itself should allow for incorporation of quality and equity issues. The 2015 oncological care reform in Poland was focused on cancer diagnostics and treatment; thus, the review of European experiences is limited to these two stages of care. Ernst and Young developed a report comparing these elements of cancer care in several high-income, mainly European countries. 25 The authors concluded that despite the differences in health system organization, all analyzed countries had implemented oncological care reforms aimed at improving health outcomes with simultaneous cost-containment targets. Also, several common features of cancer care organization can be identified, including functioning of specialized cancer centres; implementation of good practice guidelines and patient pathways; introduction of multidisciplinary team consultations; setting maximum waiting times for diagnostic and treatment access; launching a care coordinator role; and setting financial incentives to improve outcomes and/or quality of care. 25 Table 2 presents a general overview of these elements in the chosen European countries. In general, there is a great emphasis on evidence-based and coordinated cancer care in Europe. And yet, although countries have implemented similar solutions, there can be significant differences in their precise details. In 2016, the Ministry of Health published a heath care needs maps in oncology. Being part of a bigger project aimed at supporting the process of planning service distribution in accordance with present and forecasted patients' health needs, 27 the maps provided, inter alia, information on prognosed cancer incidence and the number of services needed per region in a 13-year perspective. 28 
| Implementation of the 2015 oncological package reform
The provision of cancer care in Poland is scattered across different providers. There are 18 specialized oncological centres, yet cancer care is also provided in oncological wards of multidisciplinary as well as general hospitals. These often provide only a limited scope of services, including solely, for example, image diagnostics, clinical oncology, or radiotherapy. 29 The main objective of the "oncological package" reform implemented in January 2015 was to improve e104access to cancer diagnostic and guarantee better coordination of treatment procedures. The main elements of the new system are presented in Figure 1 .
In a standard case, for each patient for whom a primary care doctor is suspicious of a malignant cancer-the oncological diagnostic and treatment card (Karta diagnostyki i leczenia onkologicznego-DILO) is issued. The card gives patient the right to access the fast track diagnostics and treatment process, which is not subject to the public payer financial limits. The original maximum waiting time limits were set at 35 days for initial and 28 days for in-depth diagnostics procedures, while the amendments from July 2017 shortened both limits to 28 and 21 days, respectively. The aim of the initial diagnostic is to confirm or exclude cancer, while the in-depth one is to assess the severity of the disease. The amendments from 2017 also introduced the possibility of specialist doctors (in addition to primary care physicians) issuing the oncological card. This change was aimed at limiting the cases when patients with confirmed cancer (by a specialist in a hospital or out-patient unit) had to visit a primary care doctor only to get the card issued.
After completion of the diagnostics phase, the therapeutic process is initiated by organization of a multidisciplinary team consultation meeting. The consultation must involve a specialist in oncological surgery (depending on the cancer location); a clinical oncologist; and/or hematologists. Initially, the participation of a physician specialized in radiology was also required (no longer obligatory since 2017). The aims of the multidisciplinary consultations are to discuss, determine, and propose the therapeutic treatment process which should then be initiated within 14 days of the consultation meeting date. Formally, at the stage of multidisciplinary team consultation meeting, the hospital should also appoint the cancer care coordinator, responsible for coordination of the treatment process and providing information to the patient. The coordinator should assure the completeness of the patient's medical records, including those entered into the DILO card. The therapeutic process ends with the decision to cease treatment and closure of the DILO card. The coordinator should then send the card, together with relevant diagnostics test results, to the patient's primary care doctor. The reform also introduced a financial penalty for providers that are not able to keep the waiting time limits-they are paid only 70% of the services contracted value.
According to the public payer data, the number of DILO cards issued per year was 233 thousand in 2015; 190 thousand in 2016; and 216 thousand in 2017. The relatively higher number of cards issued in 2015 was related to the inclusion of patients with confirmed cancer prior the reform implementation. After the reform implementation, the average waiting time for diagnostics and treatment for patients covered by the new system (with a DILO card) was significantly shortened in comparison to those excluded (without DILO) 30, 31 (Figure 2 ). Yet, according to the Supreme Audit Office analysis, this was not connected with improvements in detecting cancers at earlier stages or improvements in quality and/or comprehensiveness of care. 30 In case of the former, the auditors emphasized low intensity of diagnostic procedures performed by primary care doctors. Analysis conducted on chosen 15 primary care qualified, yet did not have a DILO card issued was almost 52 thousand (as a consequence, these patients had no access to the oncological therapy fast track). 30 
| DISCUSSION AND CONCLUSIONS
Reforms in the health system, as in any other sector, face both the challenges of consistent design as well as the challenges of successful implementation. 32 In the case of Polish oncological care reform, problems related to both dimensions can be identified. Analyses conducted by the Supreme Audit Office indicated that the reform was implemented without prior impact analysis of introduced changes and adequate preparation. Most importantly, the opinions of medical associations (eg, on allowing specialist doctors to issue the DILO card) were not included in the first version of the regulation. In general, the public consultation process of the proposed regulations was too short and aimed rather at fulfilling the formal criteria of the legislative process than at actually involving all relevant stakeholders in planning the reform. 30 The implementation stage was accompanied by massive protests of primary care doctors, who refused to take additional obligations without adequate financial compensation. In general, the information on the implemented changes provided to both patients and providers was not sufficient. 30, 33 Although Poland was one of the last European countries to develop a national cancer control programme, 34 the Strategy has been in place since 2014. It clearly indicates the need for a comprehensive approach, including all stages of prevention until the after-treatment phase. This is in line with international guidelines which from an initial focus on information systems, prevention and cancer control have extended their scope to include the aspects of psychooncology, quality-of-life, and palliative care, as well as building population-based cancer registry data systems to assess the outcomes of care. 5 In Poland, the oncological package reform did not include the post-treatment phase.
The care coordinator role ends with DILO card closure, even though the patient might still need rehabilitation and/or palliative care. Examples from other European countries show a broader scope of the cancer care coordinator role, including post-treatment rehabilitation (in England) 35 and/or follow-up monitoring in cooperation with municipalities and/or general practitioners (in Denmark and Norway). 36 There are also countries where oncological patients are included in chronic disease management, for example breast cancer management programmes in Germany or cancer care networks in France. 37, 38 The Polish reform also did not include any solutions regarding treatment outcome measurement and monitoring. The waiting time limits for diagnostics and treatment were set, yet, in terms of the efficiency objectives, the collection and transparent reporting of patient-relevant outcome data is highly recommended. 39, 40 In 2018, the Polish Ministry of Health published the indicators list, which according to the official document are "to be used to monitor the efficiency of cancer diagnostics and treatment". The list includes 36 indicators categorized into three groups according to the type of cancer (breast, lung, and colon), yet none of the indicators includes patient-related outcome, or biomedical data. They are mainly related to time and/or frequency of the diagnostics and treatment procedures. 41 Cancer prevention constitutes by itself a broad and complex topic. Yet in reforms aimed at improving health outcomes, it cannot be neglected. According to the WHO estimates between 30% and 50% of cancers can be prevented by avoiding risk factors and implementing evidence-based prevention strategies. 1 In Poland cancer prevention, both primary and secondary constitutes a huge challenge. More than one billion PLN was spent on the previous version of the National Programme Against Cancer (for the period 2006-2015), yet none of its main objectives related to inhibiting the growth of cancer incidence and improving earlier detection have been realized. 29 As a consequence, intensified actions are needed so that improving the efficiency of prevention programmes will not only be declared in strategic documents, but also executed in practice.
The oncological package reform improved access to diagnostics yet did not tackle the problem of fragmented care provision. This however is strongly related to the structure of care providers, with numerous smaller units offering only a limited scope of services. For example, in the case of surgical procedures in oncology, at least 50% of the providers offering such procedures cannot simultaneously conduct surgical pathology examinations due to the lack of adequate equipment or an employed pathologist. 29 As a consequence, the recommended action is centralization of specialized oncological treatment, also in relation to specific types of cancers. This should be accompanied by shifting some elements of care provision, related not only to diagnostics but also chemotherapy and radiotherapy from in-patient to out-patient settings. These types of solutions have been recommended by numerous Polish national experts as contributing to both the cost-containment objectives and improvement in health outcomes. 20, 29, 42 Planning and implementation of any reform should be accompanied by securing adequate resources, including both human and financial. When comparing the situation in Poland to other European countries, one must bear in mind that the total expenditure on health in Poland is relatively low. The spending per capita was equal to 1704 $PPP in 2015, while the average value in the EU was nearly two times higher. Looking at expenditure as a share of GDP, the level in Poland was nearly stable in recent years (6.4% in 2015)-lower than the EU average by about 2 percentage points. 43 It is then not surprising that the expenditure on oncological care in Poland in relation to other EU countries is also low (42 Euro per capita in 2011), eg, in the Czech Republic it is two times and in France over three times higher. 42 Implementation of the oncological package reform was not connected with increased financing. 29 In conclusion, the oncological package reform in Poland introduced some of the solutions existing in other European countries. These include most importantly: waiting time limits, multidisciplinary medical consultations, and a care coordinator position. Three years after the reform implementation, the positive effects of only the first element have been measured and reported-patients under the new system have significantly shorter waiting time for both diagnostics and treatment than those undergoing standard procedures. Research evaluating the reform impact on other elements of care, including, for example biomedical indicators, quality of care and/or economic aspects, are needed.
